Revolutionary Injectable Asthma Treatment Marks First Breakthrough in 50 Years

A new clinical trial has shown that benralizumab, a monoclonal antibody, is more effective than steroids in reducing symptoms of asthma and COPD flare-ups. The drug, already approved for severe asthma, targets eosinophils, white blood cells that cause lung inflammation. Participants in the trial experienced fewer attacks and improved quality of life compared to those on steroids. This development could revolutionize treatment for asthma and COPD, which have seen little change in treatment options over the past fifty years.